Proteinuria: an ignored marker of inflammation and cardiovascular disease in chronic hemodialysis by Trimarchi, Hernán et al.
© 2012 Trimarchi et al, publisher and licensee Dove Medical Press Ltd.   This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nephrology and Renovascular Disease 2012:5 1–7
International Journal of Nephrology and Renovascular Disease Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1
ORIgINAL ReseARch
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJNRD.S27675
Proteinuria: an ignored marker of inflammation 
and cardiovascular disease in chronic hemodialysis
hernán Trimarchi1
Alexis Muryan2
Mariana Dicugno2
Pablo Young3
Mariano Forrester1
Fernando Lombi1
Vanesa Pomeranz1
Romina Iriarte1
María soledad Raña1
Mirta Alonso2
1Nephrology, 2Biochemistry, 3Internal 
Medicine services, hospital Británico 
de Buenos Aires, Argentina
correspondence: hernán Trimarchi 
Nephrology service, hospital Británico, 
Perdriel 74 (1280),  
Buenos Aires, Argentina 
Tel +54 11 4309 6400 
Fax +54 11 4304 3393 
email htrimarchi@hotmail.com
Background: Cardiovascular disease is the leading cause of morbidity and mortality in 
hemodialysis (HD) patients, the main etiologies being diabetes and hypertension. Cardiac and 
inflammatory biomarkers are usually employed to assess risk or damage, or during follow-up. 
Proteinuria is considered a strong predictor of morbidity, a cause of inflammation, oxidative 
stress, hemodynamic alteration, and progression of chronic kidney disease. However, proteinuria 
is rarely considered in the clinical assessment of HD patients.
Methods: This was a concurrent, cohort-observational, cross-sectional study in which 
52 chronic HD subjects were divided into three groups according to the degree of proteinu-
ria: Group (G) A: ,1 g/day, n = 25; GB: 1–3 g/day, n = 13; GC: .3 g/day, n = 14. Baseline 
hemoglobin,   albuminemia, cholesterol, body mass index, Malnutrition-Inflammatory Score, 
pro-B-type natriuretic peptide, troponin T, C-reactive protein (CRP), and ultrafiltration rates 
were analyzed.
Results: There was no difference between groups in terms of baseline age, gender, 
hypertension, cause of renal failure, hemoglobin, cholesterol, albumin, CRP levels, cardiac 
biomarkers, adiponectin, body mass index, or Malnutrition-Inflammatory Score. Time on HD: 
GA, 34.56 ± 23.3 (range [r]: 6–88); GB, 25.15 ± 19.40 (r: 6–58); GC, 18.21 ± 9.58 (r: 6–74) 
months; P = 0.048. Proteinuria: GA, 0.33 ± 0.30 (r: 0.0–0.88); GB, 1.66 ± 0.54 (r: 1.03–2.75); 
GC, 7.18 ± 2.80 (r: 3.04–21.5) g/day; P , 0.001. Mean ultrafiltration rates were significantly 
different: GA, 2.80 ± 0.73; GB: 1.85 ± 0.96 liters/session; P = 0.003. Fourteen diabetic patients 
were identified (27%): GA, 3 (12%); GB, 3 (23%); GC, 8 (57%); P = 0.009. A positive and 
significant correlation was observed between diabetes and proteinuria .3 g/day: rho 0.438, 
P = 0.027. Although troponin T, pro-B-type natriuretic peptide, adiponectin, and CRP were 
not different among groups, the positive correlation between troponin T and CRP elevated 
significantly as proteinuria increased: GA, rho 377, P = 0.063; GB, rho 663, P = 0.013; GC, 
rho 687, P = 0.007.
Conclusion: In chronic HD, nephrotic-range proteinuria was significantly higher in diabetic 
nephropathy patients versus other causes. This was associated with inflammation and cardiac 
stress and was independent of fluid removal. Proteinuria .3 g/day was associated with shorter 
time on HD. Whether severe proteinuria is associated with shorter survival in HD,   independent of 
diabetes, is to be determined. Proteinuria should be considered in the assessment of cardiovascular 
and inflammatory states in HD patients.
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morbidity and mortality in individuals with chronic kidney 
disease (CKD) are, among others, protein-energy   wasting, 
malnutrition, inflammation, and the interrelationships 
between these that may emerge. There are several clinical, 
nutritional, and biochemical parameters that may be indica-
tive of a chronic inflammatory state in individuals with 
CKD, particularly those on dialysis.1 Many risk factors and 
metabolic alterations observed in the uremic milieu may 
contribute to the excessive risk of cardiovascular disease. 
Both the Framingham cardiac risk score2 and the so-called 
nontraditional risk factors, such as inflammation, endothelial 
dysfunction, sympathetic overactivation, protein-energy 
wasting, oxidative stress, vascular calcification, and volume 
overload, may play relevant roles in the development of 
vascular disease in dialysis patients.2–5 However, Wang et al6 
have recently demonstrated that the addition of multimarker 
scores (including markers of inflammation and volume 
overload) to conventional risk factors resulted only in small 
increases in the ability to grade risk, at least in the general 
population.7
Proteinuria is another predictor of increased cardiovas-
cular risk in the general population.8 Numerous studies have 
shown that treating patients with diabetic/nondiabetic CKD 
and proteinuria reduces proteinuria and slows progression of 
renal disease, and that the greater the reduction in proteinuria, 
the greater the benefit.9–11 In addition to predicting CKD 
progression, proteinuria is a well-established risk marker for 
cardiovascular disease.12–15 Reduction in proteinuria confers 
significant reduction in cardiovascular events. The Reduction 
in End Points in Noninsulin-Dependent Diabetes Mellitus 
with the Angiotensin II Antagonist Losartan (RENAAL) 
study showed that albuminuria is the most important factor 
in predicting the cardiovascular risk in patients with type 2 
diabetic nephropathy and, at 6 months, for every 50% reduc-
tion in albuminuria, an 18% reduction in cardiovascular 
risk and a 27% reduction in heart failure was reported.16 It 
is evident that proteinuria has tremendous predictive value 
in cardiac failure, both as a marker of future events and as 
a therapeutic target.9 Patients with diabetic nephropathy 
and proteinuria .3 g/g have a 2.7-fold higher risk for heart 
failure when compared with patients with low proteinu-
ria (,1.5 g/g).16 Moreover, proteinuria has been shown 
to be the strongest predictor of cardiovascular outcomes, 
including hospitalization for heart failure.16 Extinguishing 
proteinuria by decreasing blood pressure, hyperfiltration 
states, and sodium intake, as well as tightly controlling 
  glycemia, are generally accepted potential strategies to reduce 
cardiovascular risk events.9 Although the nature of the links 
between proteinuria and vascular disease may be partly due 
to endothelial dysfunction, persistent low-grade inflammation 
also plays a role. Indeed, inflammation is associated with both 
endothelial dysfunction and albuminuria.17,18
It is noteworthy, despite this active attempt to reduce 
proteinuria in predialysis patients to delay disease progression, 
proteinuria appears to be forgotten or even ignored by 
nephrologists once a patient enters dialysis. However, its 
existence may certainly continue conferring the well-known 
inflammatory, catabolic, thrombotic, and toxic effects on the 
endothelium that it exerts in the predialysis period.18–20 In this 
study, the different degrees of proteinuria in chronic hemo-
dialysis (HD) patients were determined and its association 
with nutritional, inflammatory, and cardiovascular markers 
of disease was assessed.
Methods
Design
Concurrent, cohort-observational, cross-sectional study on 
52 chronic HD patients.
Patients
The Institutional Review Board of the Hospital Británico de 
Buenos Aires was notified about the collection of data for 
the cross-sectional study. Informed consent was obtained 
from each patient enrolled. Patients aged below 18 or over 
85 years, or with a history of neoplasia, acute infection, 
hepatopathy, nontreated hypothyroidism, anuria, or body 
mass index .40 kg/m2 were excluded. No patients with 
human immunodeficiency virus, hepatitis B virus, or   hepatitis   
C virus were included. No failed transplant patients were 
included. There was no difference in history of tobacco 
use among the groups: Group (G) A: 3; GB: 1; GC: 1. Out 
of 58 patients examined, 52 chronic HD patients who had 
been treated for more than 3 months were included; six 
patients were excluded due to anuria: one due to bilateral 
  nephrectomy, two due to polycystic kidney disease, and three 
due to primary glomerulonephritis.
Patients were divided into three groups according to the 
degree of proteinuria: GA, proteinuria ,1 g/day (n = 25); GB, 
proteinuria 1–3 g/day (n = 13) and GC, proteinuria .3 g/day 
(n = 14).
Blood measurements
The following blood measurements were taken for each 
enrolled patient: C-reactive protein (CRP), hemoglo-
bin, albumin, Malnutrition-Inflammatory Score (MIS), 
pro-B-type natriuretic peptide (pro-BNP), troponin T, International Journal of Nephrology and Renovascular Disease 2012:5 submit your manuscript | www.dovepress.com
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adiponectin, and mean intradialytic ultrafiltration rate. 
Nutritional assessment was performed employing the MIS, 
and this was updated in the authors’ center every 3 months 
while the anthropometric measurements were obtained at 
the end of a dialysis session at the end of the respective tri-
mester. Hemoglobin,   cholesterol, and serum concentrations 
of albumin were measured by routine procedures. High-
sensitivity CRP (normal value: ,0.3 mg/dL) was calculated 
by immunoturbodimetry using a VITROS 5.1® FS Chem-
istry System (Johnson & Johnson, New Brunswick, NJ). 
For pro-BNP, a chemoluminiscence method was employed 
using a VITROS ECi®   Immunodiagnostic System (Johnson 
& Johnson): (normal values: ,125 pg/mL for subjects ,75 
years; ,450 pg/mL for subjects .75 years). Troponin T was 
measured by electrochemoluminiscence, using a Cobas e411 
immunology analyzer (Roche Diagnostics, Indianapolis, IN) 
  (normal value: ,0.01 ng/mL). Adiponectin was determined 
by DIAsource ELISA KAPME09 (Linco Corp, Littlerock, 
CA) (normal values: female, 10.2 ± 4.6 µg/mL; male, 
6.8 ± 4.1 µg/mL). Blood was drawn in fasting conditions prior 
to the HD session.   Proteinuria was collected as a 24-hour 
urine sample; collection started the day before blood would 
be drawn (ie, the day of the dialysis session).  All biochemi-
cal measurements were done at the Central Laboratory of 
the Hospital Británico.
hD aspects
Thrice-weekly HD sessions were performed using biocom-
patible membranes (Polyflux 10 L®; Gambro,   Stockholm, 
  Sweden) and bicarbonate bath and with a mean dialysis 
blood flow rate of 450 ± 50 mL/minute, and dialysate flow 
rate of 500 mL/minute and a mean duration per session of 
4.0 ± 0.5 hours. The ultrafiltration rate employed in this study 
was the one registered by the automatic dialysis machines 
(Surdial 190; Nipro®, Osaka, Japan) when the blood samples 
were collected. Kt/V and normalized protein catabolic rate 
(nPCR) were calculated (Table 1).
Arteriovenous accesses
Arteriovenous access was fistulae in 29 patients (56%), 
polytetrafluoroethylene grafts (Gore-tex® vascular graft; 
WL Gore and Associates, Inc, Newark, DE) in ten patients 
Table 1 general patient data
Patient characteristics Group A  
Proteinuria ,1 g/day  
(n = 25)
Group B  
Proteinuria 1–3 g/day  
(n = 13)
Group C  
Proteinuria .3 g/day  
(n = 14)
Age (years) 68.85 ± 11.85 59.72 ± 19.06 61.48 ± 16.27
gender 
  Males 
  Females
 
17 (68%) 
8 (32%)
 
8 (61.5%) 
5 (38.5%)
 
11 (78.6%) 
3 (21.4%)
Time on hemodialysis  
(months)*
34.56 ± 23.3 
(r: 6–88)
25.15 ± 19.40 
(r: 6–58)
18.21 ± 9.58 
(r: 6–74) 
Diabetics* 
16.4 ± 4.5 
Nondiabetics* 21.6 ± 2.3
hypertensives, n = 32 (61.54%) 17 (68%) 7 (53.8%) 8 (57.1%)
Diabetics,** n = 14 (27%) 3 (12%) 3 (23%) 8 (57%)
Urinary output (mL/day) 756 ± 367 688 ± 299 606 ± 382
Proteinuria*** (g/day) 0.33 ± 0.3  
(r: 0.0–0.88)
1.66 ± 0.54  
(r: 1.03–2.75)
7.18 ± 2.80  
(r: 3.04–21.5)
cholesterol (mg/dL) 179 ± 21 198 ± 37 188 ± 35
Albumin (g/dL) 3.99 ± 0.37 3.94 ± 0.36 3.70 ± 0.56
cRP (mg/dL) 1.44 ± 2.61 0.82 ± 1.07 1.10 ± 1.41
Pro-BNP (pg/mL) 23581 ± 48341 12053 ± 32318 15621 ± 41695
Troponin T (ng/mL) 0.06 ± 0.06 0.03 ± 0.02 0.06 ± 0.06
Adiponectin µg/mL 12.16 ± 7.55 12.99 ± 10.95 13.67 ± 7.29
MIs 4.92 ± 2.33 5.00 ± 1.88 4.79 ± 3.12
Body mass index 27.02 ± 4.16 25.76 ± 4.58 27.73 ± 5.63
Ultrafiltration rates (L/session) 2.08 ± 0.72 1.85 ± 0.5 2.22 ± 1.17
Kt/V 1.33 ± 0.1 1.29 ± 0.1 1.31 ± 0.1
nPcR (g/kg/day) 1.05 ± 0.27 1.11 ± 0.38 1.09 ± 0.49
Notes: *P , 0.048; **P , 0.009; ***P , 0.001.
Abbreviations: MIS, malnutrition-inflammatory score; nPCR, normalized protein catabolic rate; r, range; CRP, C-reactive protein; Pro-BNP, pro-B-type natriuretic peptide.International Journal of Nephrology and Renovascular Disease 2012:5 submit your manuscript | www.dovepress.com
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(19%), tunneled catheters (Tessio® [Medcomp®, Harleysville, 
PA] or Quinton® PermcathTM [Covidien AG, Mansfield, MA]) 
in 13 patients (25%). Nonsignificant differences according to 
access distribution were reported among the three groups.
hypertension
Patients with blood pressures .140/90 mmHg were 
considered to be hypertensive.
cardiovascular disease
Cardiovascular disease was defined as the presence, based on 
clinical grounds, imaging and laboratory results, of cardiac 
ischemic disease, and/or peripheral vascular disease and/or 
cerebrovascular disease at the time of the study.
Medications
Most of the patients were on angiotensin-converting enzyme 
inhibitors, angiotensin II receptor blockers, beta block-
ers, aspirin, or other commonly used drugs at stage 5 
chronic renal disease (such as calcium salts, potassium che-
lators, erythropoietin, intravenous L-carnitine, intrave-
nous iron, statins, omeprazole, folic acid, vitamins, and   
benzodiazepines).
statistics
Results are expressed as the median (range [r]), unless stated 
otherwise. Fisher’s exact or chi-square tests were employed 
for categoric variables. For continuous variables, the Mann–
Whitney test was used and for intervariable correlations. 
Spearman’s rank and ρ (rho) coefficient were also calculated. 
P values #0.05 were considered significant.
Results
Patients were not different according to baseline mean 
age (years): GA: 68.85 ± 11.85; GB: 59.72 ± 19.06; GC: 
61.48 ± 16.28; P = nonsignificant. Gender; hypertension; 
cause of renal failure; hemoglobin; cholesterol; albumin; CRP 
levels; cardiac biomarkers troponin T, pro-BNP, and adiponec-
tin; MIS; Kt/V; nPCR; and ultrafiltration rates were included 
(Table 1). Time on HD: GA, 34.56 ± 23.3 (r: 6–88) versus 
GB, 25.15 ± 19.40 (r: 6–58) versus GC, 18.21 ± 9.58 (r: 6–74) 
months, P = 0.048 (Table 1). Proteinuria: GA, 0.33 ± 0.30 (r: 
0.0–0.88); GB, 1.66 ± 0.54 (r: 1.03–2.75); GC, 7.18 ± 2.80 
(r: 3.04–21.5) g/day, P , 0.001. Proteinuria was present in 
87% of the dialysis population. When considering all study 
patients included, only seven (13%) patients from GA did not 
have proteinuria (all other GA patients had proteinuria, and 
all patients from GB and GC had proteinuria). No differences 
Table 2 group c characteristics
Variable Group C  
Proteinuria .3 g/day,   
n = 14
Diabetes mellitus 8
glomerulonephritis 5
Polycystic kidney disease 1
Overall proteinuria (g/day) mean ± sD 7.18 ± 2.80
Proteinuria in diabetics, n = 8 (g/day) 6.57 (r: 3.19–21.5)
Proteinuria in nondiabetics, n = 6 (g/day) 5.36 (r: 3.04–10.7)
Arteriovenous fistula 5
Arteriovenous grafts 3
catheters 6
cRP (mg/dL), median 0.45 (r: 0.1–4.6)
Pro-BNP (pg/mL), median 1475.0 (r: 149–15,800)
Troponin T (ng/mL), median 0.032 (r: 0.01–0.22)
Adiponectin (µg/mL), median 14.36 (r: 3.49–24.48)
MIs, median 3.50 (r: 2–11)
Body mass index, median 28.15 (r: 20.1–41.3)
Ultrafiltration rates, median (L/session) 2.4 (r: 0.5–4)
Abbreviations: sD, standard deviation; cRP, c-reactive protein; MIs, malnutrition-
inflammatory score; Pro-BNP, pro-B-type natriuretic peptide.
were observed with regard to vascular accesses among the 
three groups. Hypertensive subjects: n = 32, 61.54%; GA: 
17 (68%); GB: 7 (53.8%); GC: 8 (57.1%). Fourteen diabetic 
patients were identified (27%): GA, 3 (12%); GB, 3 (23%); 
GC, 8 (57%), P = 0.009. A positive and significant correlation 
was observed between diabetes and proteinuria .3 g/day: rho 
0.438, P = 0.027. Causes of end-stage renal disease in GC are 
shown in Table 2. In GC, median proteinuria between diabetics 
(n = 8) versus nondiabetics (n = 6): 6.57 (r: 3.19–21.5)   versus 
5.36 (r: 3.04–10.7) g/day, P = nonsignificant. Although tro-
ponin T, pro-BNP, and CRP were not different among groups, 
the positive correlation between troponin T and CRP elevated 
significantly as proteinuria increased: GA, rho 377, P = 0.063; 
GB, rho 663, P = 0.013; GC, rho 687, P = 0.007.
Discussion
In CKD patients, proteinuria is a common event, irrespective of 
cause, and virtually all patients with CKD present with   varying 
degrees of proteinuria.21 However, in dialysis patients, the 
prevalence of proteinuria is unknown. In the present study, pro-
teinuria was present in 87% of the   hemodialyzed population. It 
is noteworthy that, despite   significant differences in proteinuria 
among the three groups, these changes were not accompanied 
by   significant alterations in albuminemia or cholesterolemia. 
This   phenomenon could be attributed to the similar nutritional 
status the three groups displayed and to the use of statins in 
virtually all patients. In patients with proteinuria .3 g/day, 
the two main causes of end-stage renal disease were diabetes 
nephropathy and primary glomerulonephritis, although no International Journal of Nephrology and Renovascular Disease 2012:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5
Proteinuria and hemodialysis
significant differences in the amount of proteinuria between 
diabetics and subjects with glomerulonephritis were observed 
between both subpopulations. However, there was a significant 
increase in diabetic patients in GC in comparison to the other 
two groups, and a relative increase in the diabetic population 
was observed as proteinuria augmented. Proteinuric levels 
did not correlate with body mass index or the type of vascular 
access, and could not be attributed to hypertension or to hemo-
dynamic fluctuations, as pro-BNP measurements were not 
different among the groups. There was a significant difference 
in the ultrafiltration rates between GA and GB, but this could 
not be associated to any of the variables under consideration, 
particularly with pro-BNP or adiponectin, between which 
important feedback regulations exist. Interestingly, as shown 
in Table 3, as proteinuria worsened, a significant correlation 
developed between troponin T, a cardiovascular biomarker, 
and CRP, an inflammatory marker. This interrelationship 
may suggest that proteinuria could interact covertly and be 
an ignored culprit in the complex and chronic protein-energy 
wasting syndrome dialysis patients live in, contributing to 
a higher risk of cardiovascular disease and inflammation as 
proteinuria worsens.
In one of our local databases belonging to CKD patients 
recruited in year 2010, proteinuria was present in 204 subjects 
(76.98%). Interestingly, proteinuria significantly worsened as 
kidney function declined and the highest rates of proteinuria 
were encountered in the most advanced stages of the cohort: 
Stage 3, 1.39 ± 3.2 g/day (r: 0.0–21.6) in 80% of the 90 cases 
included versus Stage 4, 1.87 ± 0.99 g/day (r: 0.0–5.1), 
which represented 95% of the 37 individuals included in this 
group. At Stage 5D, proteinuria was present in 85% of the 
60 patients included and the mean level of proteinuria was 
2.48 ± 3.72 g/day (r: 0.0–21.5). This level of proteinuria was 
significantly higher and different from Stages 3 (P = 0.001) 
and 4 (P = 0.013). These findings underscore previous find-
ings that demonstrated that proteinuria is associated with 
CKD, worsens renal function, and is highly prevalent in 
end-stage renal disease.9–11,21
Cardiovascular disease is the main cause of death in the 
CKD population. However, cardiovascular disease can be 
the final pathophysiological pathway where many different 
entities may converge: Framingham factors,   malnutrition, 
oxidative stress, calcium-phosphate metabolism,   anemia, 
infections, and inflammation. Although many of the 
traditional Framingham risk factors have been included in this 
study, only diabetes mellitus was significantly more frequent 
in GC compared with the other groups (Table1). In CKD, 
the main causes that lead to renal replacement therapies are 
diabetic nephropathy, hypertension, and glomerulonephritis. 
In all these entities, cardiovascular disease is a major cause 
of morbidity and mortality, and proteinuria again plays a 
key role in these pathophysiological processes. In this study, 
higher degrees of proteinuria (.3 g/day) significantly cor-
related with troponin T and CRP, markers of cardiovascular 
stress and systemic inflammation (Table 3).
The question is, therefore, what the relationship among 
CRP, troponin T, and proteinuria in HD is, if indeed there 
is such a relationship. Both CRP and troponin T have been 
employed as markers of highly prevalent complications as 
inflammation and cardiovascular disease in dialysis subjects. 
CRP has been reported to be elevated in 30%–60% of dialysis 
patients and can be employed as a predictor of cardiovascular 
mortality in HD.22 In addition, it has been established that 
troponin T levels are increased in subjects with renal   failure, 
even in the absence of myocardial ischemia.23,24 In fact, 
approximately 53% of patients with CKD present with elevated 
troponin T without acute myocardial necrosis.25 As troponin T 
is normally cleared by the kidneys, it could be elevated in CKD 
owing to delayed clearance.26 However, other reasons could 
also explain the high troponin T levels, such as left ventricular 
hypertrophy, congestive heart failure, and sepsis.24,25,27 The 
combination of increased levels of CRP and troponin T levels 
is associated with an increased risk of death in CKD.28 Wong 
et al state that the positive correlation between troponin T and 
CRP could be due to an inflammatory process that could induce 
a subclinical myocardial damage resulting from endothelial 
injury and atherosclerosis.29 How does proteinuria fit into this 
process? In dialysis, proteinuria could be an important cause 
of inflammation, endothelial dysfunction, atherosclerosis, and 
peripheral vascular disease as in previous stages of CKD,11,30 
triggering CRP and troponin T elevations. This situation could 
mean that as proteinuria worsens, the correlation found between 
troponin T and CRP increases significantly (Table 3).
Therefore, it ought to be reasonable to target proteinuria 
for treatment, as its decrease may result in better residual 
kidney function and cardiovascular status in Stage 5D 
  subjects. However, once patients are started on dialysis, 
Table 3 correlations between troponin T and c-reactive protein 
in the different groups
Group A Group B Group C
C-reactive  
protein
C-reactive  
protein
C-reactive   
protein
Troponin T ρ = 0.377 
P = 0.063
ρ = 0.663 
P = 0.013
ρ = 0.687 
P = 0.007
Note: ρ, Spearman coefficient.International Journal of Nephrology and Renovascular Disease 2012:5 submit your manuscript | www.dovepress.com
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  proteinuria is generally ignored as a potential factor of 
morbidity and mortality; but proteinuria may contribute 
to the burden of cardiovascular disease and should be paid 
attention to in dialysis patients. Therefore, despite patients 
with proteinuria being on dialysis, the condition should be 
controlled as its persistence may hasten the loss of residual 
renal function, a relevant item to preserve at any price in 
this population.
Moreover, proteinuria is not only important as a marker of 
progression of renal disease but is also associated with cata-
bolic processes, protein-energy wasting, hypoalbuminemia, 
and inflammation. All these processes are prevalent in the 
dialysis community.1,7 However, the data relating proteinuria 
and HD are more than scant. In a work published by 
Goldwasser and Kaldas in 1999, in which they observed a 
rise in albumin and creatinine in those patients who entered 
dialysis after 6 months of treatment, they hypothesized that 
this phenomenon could be attributed, in part, to a better 
nutritional status, gain in muscle mass, and to a decline in 
residual renal function.21 This decrease in urinary output 
could consequently result in lower losses of protein in the 
urine. It is well-known that as proteinuria progresses and, 
more importantly, when there is no medical intervention 
focused specifically on it, parenchymal fibrosis ensues and 
residual renal function rapidly deteriorates.
One question that needs to be addressed for dialysis 
patients is the threshold above which proteinuria could be 
implicated in inflammatory processes and contribute to the 
development of cardiovascular disease. Should the levels of 
proteinuria be interpreted in the same way as in predialysis 
subjects? This study suggests that as proteinuria increases, 
cardiovascular stress and inflammatory processes are more 
likely to be encountered. No data exists on whether pro-
teinuria should be treated in dialysis or, in that case, the 
level of treatment to pursue. The authors’ data suggest that 
proteinuria should be treated, considering its association 
with inflammation and cardiovascular stress. Although, as 
mentioned above, angiotensin-converting enzyme inhibitors 
or angiotensin II receptor blockers could have modified 
these results, the drugs were employed homogeneously in 
the three groups.
Finally, this study has found that as proteinuria worsens, 
there is a trend to shorten time on HD (Table 1). Whether this 
is due to a higher proportion of diabetic patients, who have 
a lower survival rate than nondiabetics, or to higher degrees 
of proteinuria, cannot be concluded from the present study. 
However, the authors underscore the critical importance 
proteinuria may play in HD as a forgotten, overlooked marker 
of cardiovascular disease and inflammation.
This study has many limitations. Due to the small number 
of cases included, conclusions must be drawn cautiously. 
In this respect, in GC the significant correlation found 
between CRP and troponin T may be associated with heavy 
proteinuria, but other factors not assessed in this study may 
also be involved. Other inflammatory molecules, such as 
interleukin 6 and tumor necrosis factor or endothelial and 
  procoagulant molecules like plasminogen activator inhibi-
tor-1, were unable to be measured. These molecules are more 
accurate as markers of inflammation than CRP and would 
have certainly added more information to the data presented 
in this study. Further, no vascular arteriosclerotic parameters 
such as pulse wave velocity were evaluated in the patients in 
this study, which would have certainly enriched the primary 
findings.   Moreover, as an observational study of a cross-sec-
tional cohort, no follow-up with regard to patient prognosis, 
the evolution of proteinuria and its correlation with other 
biomarkers, or mortality rates could be obtained. All these 
results require validation.   However, the authors believe this 
work will be a call to attention for nephrologists regarding 
another important aspect of the characteristics of urinary 
output and residual renal function in dialysis patients.
Conclusion
In chronic HD, diabetes was significantly associated with 
obesity. Nephrotic range proteinuria was significantly higher 
in diabetic nephropathy patients versus other causes and was 
associated with inflammation and cardiac stress. Proteinuria 
should be considered in the assessment of cardiovascular and 
inflammatory states of HD patients. Diabetes was associated 
with shorter time spent on HD. Whether severe proteinuria 
is associated with shorter survival in HD, independent of 
diabetes, is yet to be determined.
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